PBAC's latest decision on Trastuzumab deruxtecan: Recommended with restriction (2025). Considered for Treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma following progression on prior trastuzumab-containing therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
4
first 2022
Submissions
4
2022 → 2025
Eligible population
Patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma who have progressed following treatment with a trastuzumab-containing regimen, with WHO performance status no higher than 1.
Standard of care chemotherapy (paclitaxel, irinotecan, docetaxel, or FOLFIRI)
Economic model
CUA
ICER note
ICER value not provided in the publicly available text; document indicates economic evaluation was conducted but specific numeric ICER is redacted or commercially confidential.
ICER (historical)
$55k/QALY–$75k/QALY in an earlier submission (2024) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — Submission proposed a special pricing arrangement (SPA); exact terms not detailed in public text.
Submission history
Jul 2022: Recommended with restriction · Authority Required
Nov 2023: Recommended with restriction · Authority Required
Mar 2024: Recommended with restriction · Authority Required — ICER $75k/QALY
May 2025: Recommended with restriction · Authority Required